Navigation Links
SAGE Labs, Inc. Licenses CRISPR/Cas9 genome engineering technology from Caribou Biosciences, Inc.
Date:9/24/2013

ST. LOUIS, Sept. 24, 2013 /PRNewswire/ -- SAGE Labs, Inc., a leading provider of in vivo products, services and technologies in the field of genome engineering, announced today that it has entered into a partnership and licensing agreement with Caribou Biosciences, Inc. (Caribou Bio) for key intellectual property related to the CRISPR/Cas9 genome editing system.

Under the agreement, SAGE Labs will gain exclusive rights to Caribou Bio's intellectual property to produce and sell genetically engineered rats, and will gain non-exclusive rights for mouse and rabbit models.  The Cas9 system will complement SAGE's Zinc Finger Nuclease (ZFN) technology, allowing SAGE to offer customers access to novel animal models of human disease, as well as reduced turnaround times for its custom model creation platform, SAGEspeed®.

"SAGE Labs is the leader in creation of next-generation research models. As such, it is important to have access to key technologies needed to perform complex genome engineering projects," commented Dr. David Smoller, CEO of SAGE Labs. "Using Cas9 allows us to provide our customers with enhanced models that provide the most translational value for their research."

"We believe the Cas9 system will become very important in the creation of new models of human disease, both in vitro and in vivo," commented Dr. Rachel Haurwitz, CEO of Caribou Bio. "SAGE Labs' track record as a market leader in commercializing in vivo technologies will enable them to use Cas9-based engineering to bring innovative, high-quality engineered research models to the marketplace."

Please see www.sageresearchlabs.com for further details.

About SAGE Labs

SAGE® Labs is a world-class provider of next-generation research models and transgenic support services. Using proprietary platform technologies, such as Zinc Finger Nucleases (ZFN) and the CRISPR/Cas9 system for genome engineering, SAGE produces complex in vivo research models in half the time as models produced using conventional technologies. For more information, visit http://www.sageresearchlabs.com.

About Caribou Bio

Caribou Bio specializes in the research and development of technologies for cellular engineering and analysis. Caribou Bio's technologies are based on the unique capabilities of Cas enzymes from the CRISPR prokaryotic immune system. Caribou Bio's lead technology is the Cas9 enzyme, a highly efficient and easy to use genome editing platform that does not require unique protein development.

Media Contact:
Phil Simmons
(314) 313-7847
Phil.Simmons@sageresearchlabs.com

 


'/>"/>
SOURCE SAGE Labs, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. LABS, Inc. Earns AABB Accreditation for Donor Testing
2. LABS, Inc. Among Colorados Top Private Companies
3. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
4. Sigma Life Science Licenses CompoZr Zinc Finger Nuclease Technology to Horizon Discovery
5. Genomatica Licenses TeselaGen Software for DNA Design
6. Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer
7. SRI International Licenses Bed Bug Detection Technology to Redcoat, a Virginia-Based Start-Up Company
8. Personal Genome Diagnostics Inc. Licenses Genome-Mapping Technology from Johns Hopkins University and Expands Its Cancer Genome Analysis Business
9. Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
10. Syngenta Licenses Plant Sensory Systems' Technology
11. Bluechiip Licenses Its Technology in Deal with US Tech Company MiTeGen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 21, 2017 , ... ... innovative Quantum peristaltic pump with patented ReNu single-use (SU) cartridge technology. Engineered ... for high-pressure feed pumps in SU tangential flow filtration (TFF), virus filtration ...
(Date:3/22/2017)... ... ... The Society for Immunotherapy of Cancer (SITC) strongly opposes the proposed budget ... year 2018 budget request. , This proposal calls for a reduction ... 20% of its total budget. If applied proportionally across NIH, funding for the National ...
(Date:3/22/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... Lebovits , Chief Executive Officer, will provide an update ... Associates 2 nd Annual Neuroscience Biopartnering and Investment ... the New York Academy of Sciences. ...
(Date:3/22/2017)... Mass. , March 22, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... RXi,s Chief Business Officer, will present at the ... forum will provide a platform to present to ... institutes, leading pharmaceutical and biotech companies as well ...
Breaking Biology Technology:
(Date:3/23/2017)... PUNE, India , March 23, 2017 The report ... Equipment, Touchless Biometric), Industry, and Geography - Global Forecast to 2022", published by ... growing at a CAGR of 29.63% between 2017 and 2022. ... ... Logo ...
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... March 21, 2017   Neurotechnology , a ... technologies, today announced the release of the ... provides improved facial recognition using up to 10 ... single computer. The new version uses deep neural-network-based ... and it utilizes a Graphing Processing Unit (GPU) ...
Breaking Biology News(10 mins):